A detailed history of Daiwa Securities Group Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 7,900 shares of RXRX stock, worth $54,589. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,900
Previous 7,868 0.41%
Holding current value
$54,589
Previous $59,000 11.86%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.92 - $8.6 $189 - $275
32 Added 0.41%
7,900 $52,000
Q2 2024

Aug 07, 2024

SELL
$7.35 - $10.05 $23,622 - $32,300
-3,214 Reduced 29.0%
7,868 $59,000
Q1 2024

May 02, 2024

SELL
$9.13 - $15.52 $6,181 - $10,507
-677 Reduced 5.76%
11,082 $110,000
Q4 2023

Jan 31, 2024

BUY
$5.09 - $10.79 $56,132 - $118,992
11,028 Added 1508.62%
11,759 $116,000
Q2 2023

Jul 31, 2023

SELL
$4.56 - $9.94 $35,020 - $76,339
-7,680 Reduced 91.31%
731 $5,000
Q1 2023

May 02, 2023

BUY
$6.42 - $9.64 $9,681 - $14,537
1,508 Added 21.85%
8,411 $56,000
Q4 2022

Feb 06, 2023

BUY
$7.16 - $12.7 $45,050 - $79,908
6,292 Added 1029.79%
6,903 $53,000
Q3 2022

Nov 02, 2022

SELL
$7.83 - $13.6 $90,702 - $157,542
-11,584 Reduced 94.99%
611 $7,000
Q2 2022

Aug 09, 2022

BUY
$5.04 - $9.26 $24,968 - $45,874
4,954 Added 68.42%
12,195 $99,000
Q1 2022

Apr 29, 2022

BUY
$6.16 - $18.03 $13,102 - $38,349
2,127 Added 41.59%
7,241 $52,000
Q4 2021

Feb 03, 2022

BUY
$16.14 - $21.86 $82,539 - $111,792
5,114 New
5,114 $88,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.25B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.